Price Alert

Bicycle Therapeutics (BCYC)

NASDAQ: BCYC · Real-Time Price · USD

7.45

0.07 (0.95%)

At close: Aug 15, 2025, 3:59 PM

7.98

7.11%

After-hours: Aug 15, 2025, 06:34 PM EDT

0.95% (1D)

Bid	7.22
Market Cap	515.94M
Revenue (ttm)	25.73M
Net Income (ttm)	-203.27M
EPS (ttm)	-3.52
PE Ratio (ttm)	-2.12
Forward PE	-1.74
Analyst	Buy

Ask	8
Volume	201,894
Avg. Volume (20D)	288,412
Open	7.39
Previous Close	7.38
Day's Range	7.32 - 7.64
52-Week Range	6.10 - 28.67
Beta	1.45

About BCYC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BCYC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BCYC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Bicycle Therapeutics has released their quartely earnings on Aug 8, 2025:

Revenue of $2.92M misses estimates by $6.29M, with -68.81% YoY decline.

EPS of -1.14 misses estimates by -0.20, with -48.05% YoY decline.

Next Earnings Release

Bicycle Therapeutics is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

7 months ago

+13.9%

Bicycle Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

11 months ago

-7.59%

Bicycle Therapeutics shares are trading lower. The company announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate zelenectide pevedotin in metastatic urothelial cancer; BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist BT7480 in advanced solid tumors.

News

1 week ago · fool.com

Bicycle (BCYC) Q2 Revenue Falls 69%

1 week ago · businesswire.com

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc...

1 month ago · businesswire.com

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on July 1, 2025, the Compensation Committee of the company's Board of Directors granted to e...

2 months ago · businesswire.com

Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicy...